[Pharmacodynamics of allapinine during long-term infusion in patients with chronic ischemic heart disease and frequent ventricular extrasystole].
During a prolonged (24-hour) intravenous administration in a dose of 126 mg, allapinine produced a stable pronounced antiarrhythmic effect in 90% of the patients with frequent premature ventricular contraction and adverse reactions in the central nervous system in 65% of the cases. However, the latter effect of allapinine is short-term and ceased independently without altering the infusion rate. More serious adverse effects (hypotensive reactions, proarhythmic effects) occurred in 4% of the cases.
Khakimov
A G
AG
Merkulova
I N
IN
Semeĭkin
O V
OV
Frolova
E P
EP
Mansurova
G L
GL
Mazaev
A V
AV
Ruda
M Ia
MIa
D000157:Aconitine / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000097:blood / Q000494:pharmacology*; D005117:Cardiac Complexes, Premature / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D002908:Chronic Disease; D003327:Coronary Disease / Q000097:blood / Q000150:complications*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged
D000889:Anti-Arrhythmia Agents; C051402:allapinin; D000157:Aconitine
Farmakodinamika allapinina dlitel'noĭ infuzii u bol'nykh khronicheskoĭ ishemicheskoĭ bolezn'iu serdtsa s chastoĭ zheludochkovoĭ ékstrasistolieĭ.